Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects

Inclusion Criteria:

- Subject has had stable moderate to severe plaque psoriasis for at least 6 months

- Subject must be considered, in the opinion of the investigator, to be a suitable
candidate for treatment with a biologic per regional labeling

- Subject has involved body surface area (BSA) ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at
screening and at baseline

Exclusion Criteria:

- Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
medication-induced psoriasis, or other skin conditions at (eg, eczema) that would
interfere with study evaluations

- Subject has known history of Crohn's disease

- Subject has any other significant concurrent medical condition or laboratory
abnormalities, as defined in the study protocol

- Subject has stopped using certain psoriasis therapies as defined in the study protocol

- Subject has previously used any anti-IL-17 biologic therapy